X4 Pharmaceuticals (XFOR) EBITDA Margin (2018 - 2025)
X4 Pharmaceuticals posted quarterly EBITDA Margin of 922.86% for Q4 2025, up 156773.0% year-on-year from N/an in Q4 2024, and up 40.79% on a QoQ basis from 1558.58% in Q3 2025.
X4 Pharmaceuticals (XFOR) has 4 years of EBITDA Margin data on file, last reported at 922.86% in Q4 2025.
- For the quarter ending Q4 2025, EBITDA Margin rose 156773.0% year-over-year to 922.86%; the trailing twelve-month figure through Dec 2025 stood at 247.44% (up 117614.0% YoY), and the FY2025 full-year result was 247.44%, up 121729.0% from the prior year.
- EBITDA Margin for Q4 2025 stood at 922.86%, up from 1558.58% in the prior quarter.
- Across five years, EBITDA Margin topped out at 12629.31% in Q2 2024 and bottomed at 6160.71% in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.24% |
| 10 | X4 Pharmaceuticals | 182.28 Mn | 182.28 Mn | 2.20 Mn | -922.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -922.86% |
| Sep 30, 2025 | -1,558.58% |
| Jun 30, 2025 | -1,329.55% |
| Mar 31, 2025 | -32.78% |
| Dec 31, 2024 | -2,490.59% |
| Sep 30, 2024 | -6,160.71% |
| Jun 30, 2024 | 12,629.31% |
| Mar 31, 2020 | -371.27% |
| Dec 31, 2018 | -230.11% |